JAK3 Mutations ID'd in About One-Third of T-Cell Lymphomas

This article originally appeared here.
Share this content:
<i>JAK3</i> Mutations ID'd in About One-Third of T-Cell Lymphomas
JAK3 Mutations ID'd in About One-Third of T-Cell Lymphomas

(HealthDay News) – Approximately one-third of patients with natural killer/T-cell lymphoma (NKTCL) harbor somatic-activating Janus kinase 3 (JAK3) mutations, according to a study published online June 15 in Cancer Discovery.

Ghee Chong Koo, PhD, from the National Cancer Centre Singapore, and colleagues conducted whole-exome sequencing in 4 patients with NKTCLs. In 61 additional cases, the prevalence of JAK3 mutations was investigated using Sanger sequencing and high-resolution melt analysis.

In two of the four patients who underwent whole-exome sequencing, the researchers identified JAK3 somatic-activating mutations (A572V and A573V). Further analysis demonstrated that 35.4% of cases harbored JAK3 mutations. The JAK3 mutations were suggested to be involved in cytokine-independent JAK/STAT constitutive activation, leading to enhanced growth. Inhibition with the novel pan-JAK inhibitor CP-690550 resulted in dose-dependent reduction of phosphorylated STAT5, reduced cell viability, and increased apoptosis in both JAK3-mutant and wild-type NKTCL cell lines.

"In summary, our studies identified, for the first time, frequent JAK3 mutations in NKTCLs," the authors write. "They also indicated that targeting the JAK/STAT pathway in this disease is a potentially effective therapeutic approach that warrants further investigation."

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs